Background The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding evidence for using calcineurin inhibitors (CNI) ...

Background Lupus nephritis (LN) is one of the most common organ-specific injury of systemic lupus erythematosus (SLE) and has great influence on patients’ prognosis. Some research showed that ...

Case 1: Blisters in systemic lupus erythematosus Skin lesions can be very heterogeneous in systemic lupus erythematosus (SLE). Clinicopathological correlation is crucial to identify the type of ...

Background B-cells expressing B-cell receptors (BCRs) specific for self-antigens are normally eliminated, or made anergic, through negative selection during B-cell development. VH4-34 is an ...

Objective Tissue calcifications or calcinosis have been described to occur in a variety of systemic autoimmune diseases, even being a significant part of the clinical picture for example in systemic ...

Background Anti-nuclear antibodies (ANA) are common in systemic rheumatic diseases, non-rheumatic autoimmune diseases and the general population. In clinical practice, testing for ANA can inform ...

Objectives To evaluate the functional impact of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three families with SLE and hypocomplementaemic urticarial vasculitis (HUV) from the United Arab ...

Objectives Important findings can be masked in gene expression studies of mixed cell populations. We examined single-cell gene expression in SLE patient monocytes in the context of clinical and ...

Background and Aims Systemic Lupus Erythematosus (SLE) and its treatment predispose to infections such as human papillomavirus (HPV) that is a risk factor for the development of lower genital tract ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE).

Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...

Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...